Daily Stock Analysis, ALKS, Alkermes Plc, priceseries

Alkermes Plc. Daily Stock Analysis
Stock Information
Open
22.13
Close
22.18
High
22.39
Low
22.01
Previous Close
21.89
Daily Price Gain
0.29
YTD High
37.75
YTD High Date
Apr 9, 2019
YTD Low
21.29
YTD Low Date
Jun 3, 2019
YTD Price Change
-6.93
YTD Gain
-23.81%
52 Week High
51.70
52 Week High Date
Jun 19, 2018
52 Week Low
21.29
52 Week Low Date
Jun 3, 2019
52 Week Price Change
-28.59
52 Week Gain
-56.31%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 4. 2019
30.00
Jan 23. 2019
32.21
12 Trading Days
7.37%
Link
Company Information
Stock Symbol
ALKS
Exchange
NasdaqGS
Company URL
http://www.alkermes.com
Company Phone
00-353-1-772-8000
CEO
Richard F. Pops
Headquarters
-
Business Address
CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, IRELAND 00000
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Delivery
CIK
0001520262
About

Alkermes Plc is a biopharmaceutical company. It engages in the development, manufacturing and distribution of medicines. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company's marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.